Daniel Serin

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Henri Roché, P. Fumoleau, M. Spielmann et al. · Journal of Clinical Oncology · 2006 · 570 citations · Full text

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

X. Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology · 2013 · 337 citations

Breast Oncology, Medicine, Randomised Phase 3 +5

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

M. Spielmann, Henri Roché, T. Delozier et al. · Journal of Clinical Oncology · 2009 · 298 citations

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Bruno Coudert, Rémy Largillier, Laurent Arnould et al. · Journal of Clinical Oncology · 2007 · 132 citations · Full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6